This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Karlowsky, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Karlowsky, J. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2009, p. 1690-1692, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01388-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniae{triangledown}

George G. Zhanel* and James A. Karlowsky

Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Received 15 October 2008/ Returned for modification 12 December 2008/ Accepted 6 January 2009

Iclaprim, a novel dihydrofolate reductase inhibitor, inhibited 90% of the clinical isolates (MIC90) of Streptococcus pneumoniae (n = 785) collected by a national surveillance program at a concentration of 1 µg/ml. The MIC90 for iclaprim was 7 doubling dilutions lower for trimethoprim-sulfamethoxazole-susceptible isolates (n = 670; MIC90, 0.06 µg/ml) than for trimethoprim-sulfamethoxazole-resistant isolates (n = 115; MIC90, ≥8 µg/ml). The potential clinical utility of iclaprim to treat patients with pneumococcal infections may depend upon the current prevalence of resistance to trimethoprim-sulfamethoxazole in this pathogen.

* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 5th floor, Basic Medical Sciences Building, 745 Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9, Canada. Phone: (204) 787-4902. Fax: (204) 787-4699. E-mail: ggzhanel{at}pcs.mb.ca

{triangledown} Published ahead of print on 12 January 2009.

Antimicrobial Agents and Chemotherapy, April 2009, p. 1690-1692, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01388-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»